Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING

By The Northwire Desk — AI Analysis Jun 09, 2026 · 20:38 APTX NaN
APTX · Price

Executive Summary

  • Apotex Health Corp. has priced its upsized initial public offering of 54,166,670 common shares at $24.00 per share, generating total gross proceeds of approximately $1.3 billion.
  • The capital raise is structured as a primary treasury offering for the company (~$850M) and a secondary offering by existing shareholders (~$450M), with an over-allotment option for up to 8.125 million additional shares.
  • Shares are scheduled to begin trading on the Toronto Stock Exchange under the symbol "APTX" on June 10, 2026, with closing expected around June 16, 2026.

Key Details

  • Offering Price: $24.00 per Common Share
  • Total Shares Offered: 54,166,670 Common Shares
  • Total Gross Proceeds: $1,300,000,080
  • Primary (Treasury) Offering: 35,416,666 shares, generating $849,999,984 in gross proceeds to Apotex
  • Secondary Offering: 18,750,004 shares, generating $450,000,096 in gross proceeds to Selling Shareholders
  • Over-Allotment Option: Underwriters granted an option to purchase up to 8,125,000 additional Common Shares at $24.00/share, exercisable at any time until 30 days after the closing date
  • Underwriting Syndicate: Co-lead managers/joint global coordinators/joint lead bookrunners: RBC Capital Markets, TD Securities Inc., and Scotiabank; Joint bookrunners: BMO Capital Markets and Jefferies Securities, Inc.; Co-managers: CIBC Capital Markets, ATB Cormark Capital Markets, Desjardins Capital Markets, National Bank Capital Markets, MUFG, Raymond James, Bloom Burton Securities Inc., Canaccord Genuity Corp., Stifel, and Paradigm Capital Inc.
  • Legal Counsel: Goodmans LLP (Canadian counsel to Apotex), Stikeman Elliott LLP (Canadian counsel to underwriters), Kirkland & Ellis LLP (US counsel to Apotex), Skadden, Arps, Slate, Meagher & Flom LLP (US counsel to underwriters)
  • Closing Date: On or about June 16, 2026 (subject to customary closing conditions)
  • Trading & Listing: Shares will begin trading on the TSX on an "if, as and when issued" basis on June 10, 2026 under the ticker symbol "APTX"; TSX listing is conditionally approved pending customary requirements
  • Prospectus Filing: Final base PREP prospectus filed with Canadian securities regulatory authorities; supplemented prospectus containing pricing information will be available on SEDAR+ on or about June 10, 2026
Read the original news release →

More from NaN

Jul 01, 2026 · 09:00

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

M&A / Property Jul 01, 2026 · 01:47

Apotex Health receives Health Canada OK for Sevmia

Regulatory Jun 30, 2026 · 16:19

Apotex Capitalizes on GLP-1 Boom with First Canadian Generic Weight-Loss Approval Post-IPO

Regulatory Jun 16, 2026 · 08:58

Canadian pharma giant debuts on TSX with $1.5B capital raise, trading at a premium to IPO price

Financings Jun 11, 2026 · 11:18

Canadian pharma giant completes $1.3B IPO, debuts on TSX with a 12.5% pop.

Regulatory Jun 10, 2026 · 09:01

Record $1.3B life sciences IPO launches on TSX, valuing Canada's largest pharma at ~$5.6B.

Regulatory